- All Targets
- Angiogenesis/Tyrosine Kinase
- Cell Cycle/Checkpoint
- HDAC
- Apoptosis
- PARP
- Aurora/Ksp
- MAPK
- PI3K/Akt/mTOR
- Hormone
- Integrase/CCR5
- Proteases/HSP90/HSP70
- Wnt/Hedgehog/Notch
- Jak/Stat
- Ca/cAMP/Lipid Signaling
- Neuro Signaling
- TGF-beta/Smad Signaling
- GPCR
- SCTR
- SSTR
- CRF receptor
- GCGR
- GHSR
- GRF-R
- Ghrelin receptor
- tachykinin NK1 receptor
- vasopressin receptor
- Angiotensin receptor
- CB1 receptor
- CB2 receptor
- OX receptor
- Beta-1 adrenergic receptor
- Smoothened (Smo)
- Alpha-1 receptor
- A2A adenosine receptor
- mGluR2/mGluR3
- PTGFR
- SGLT
- Opioid receptor
- Dopamine receptor
- Beta-2 adrenergic receptor
- Serotonin receptor
- Muscarinic receptor
- Ion channel
- Cytochrome P450
- Others
- Cancer
- Infection
- Endocrinology
- Metabolic Disease
- Inflammation
- Immunology
- Neurological Disease
- Cardiovascular Disease
Pazopanib
(SynonymsGW786034, Votrient, Armala
)Add to Favor
M.Wt: 473.98
Formula: C21H23N7O2S.HCl
Solubility: DMSO
Purity: 98%
Storage: at -20℃ 2 years
CAS No.: 635702-64-6
Price and Availability of Pazopanib:
Applications & Customer's Feedback of Pazopanib:
-
Pazopanib was purchased from Selleck.Data from Journal of Virology 2011.March;85:2296–2303.
A,IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. The effect of inhibitors is presented as the percentage of ANDV-induced permeability of inhibitor-treated monolayers 3 days postinfection and 30 min post-VEGF and FITC-dextran addition. B, VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for Fig. 1 at indicated times in the presence or absence of Pazopanib.
-
Pazopanib was purchased from Selleck.Data from Journal of Virology 2011.March;85:2296–2303.
Dasatinib and pazopanib block VE-cadherin internalization in ANDV-infected HUVECs. Human endothelial cells were mock infected or infected with pathogenic ANDV at an MOI of 0.5. Three days postinfection, endothelial cells were pretreated with kinase inhibitors dasatinib (1 nM/liter) and pazopanib (100 nM/liter) or left untreated for 15 min prior to VEGF addition (100 ng/ml, 2 h). Cells were incubated with an antibody to the extracellular domain of VE-cadherin (BV9; Clonetics) at 4°C for 1 h (23, 26, 31). After antibody removal and washing, cells were incubated at 37°C in 5% CO2 (31) (1 h) to permit intracellular trafficking of antibody-bound VE-cadherin (23). Cells were subsequently washed with a mild acid solution (2 Mm PBS-glycine, pH 2.0; three times for 5 min each) in order to remove VE-cadherin antibody that was not internalized or were left untreated (23, 26, 31). Cells were paraformaldehyde fixed and Triton X-100 permeabilized prior to incubation with an FITC-tagged anti-mouse secondary antibody and examined on an Olympus IX51 microscope. Data are presented as a percentage of cells with internalized Vecadherin in ANDV-infected ECs pretreated only with VEGF (control) versus mock-treated infected cells (n 500; P 0.001) (31). Data represent the results from two independent experiments.
Biological Activity of Pazopanib:
VEGFR enzyme assays for VEGGR1,VEGFR2, and VEGFR3 were running in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3.
Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively. Significant activity was also seen against the closely related tyrosine receptor kinases PDGFR beta, c-Kit, FGF-R1, and c-fms with IC50’s of 84, 74, 140,and 146 nM, respectively. In cellular assays, in addition to inhibiting the VEGF-induced proliferation of HUVECs, Pazopanib potently inhibited VEGF-induced phosphorylation of VEGFR-2 in HUVEC cells with an IC50 of ∼8 nM.
The cytochrome P450 profile was also improved with inhibition >10 μM against the isozymes tested, with the exception of 2C9 (7.9 μM). [1]
References on Pazopanib:
MSDS
Batch S103501: H-NMR HPLC COA
Batch S103502: H-NMR HPLC COA
Batch S103503: H-NMR HPLC COA
Batch S103504: H-NMR COA
Batch S103505: H-NMR COA
Batch S103506: H-NMR HPLC COA
VEGFR-PDGFRWe give free samples and rewards to people who would like to provide us useful scientific data(western blot, etc.) See Details
Find Multiple Products by Catalog Number
| Dongfeng Chen, The Rausing Lab |
| "Your product U0126(Cat.NO S1102) works well in our experiments. I hope I can get more excellent products from your company in future." |
| R.B. Cambridge |
| "I have used the chemical that I bought from you(Selleck,PTC-124) and it worked well.So we will eventually be ordering more." |
| Zhenghe John Wang Assistant Professor, Case Western Reserve University |
| "We have purchased LBH-589, Saha and MS-275 from you and they all worked well." |
| Jenny Sun |
| "We used the LBH-589 in our experiments. The compound is easy to use with excellent reproducibility." |
| Yu Wang, Harvard University |
| "The GDC0449 compound worked very well. The results in my hands are equally good as what's been published. Thanks for this great resource for our research." |
| Dung-Fang Lee |
| "Based on our preliminary data, I found MLN8237 and VX-680 have good effects in inhibiting Aurka-maintaining ESC self-renewal in mouse ES cells." |
| Jun 2011 Selleck Latest Catalog | ![]() |



